Abstract Library

#1503 Impact of Prior Somatostatin Analogue (SSA) Use on Progression-free Survival (PFS) in Patients with Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: A Secondary Analysis from the RADIANT-4 Study

Introduction: In the RADIANT-4 study, everolimus (EVE) reduced the risk of disease progression or death by 52% vs placebo (PBO; P<0.00001) in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET of lung/GI tract.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Buzzoni R

Authors: Buzzoni R, Carnaghi C, Pommier R, Fazio N, Singh S,

Keywords: everolimus, SSA, nonfunctional NET,

#1502 Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from the Phase 3 RADIANT-4 Study.

Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Pommier R

Authors: Pommier R, Strosberg J, Singh S, Wolin E, Yao J,

Keywords: Everolimus, nonfunctional NET, prior chemotherapy,